Marijo Bilusic, MD, PhD
Fox Chase Cancer Center
333 Cottman Ave
Philadelphia, PA 19111-2497
Kidney Cancer Awareness Week
Dr. Bilusic speaks to Harry Hurley, WPG 1450 AM in Atlantic City, about kidney cancer and treatment options at Fox Chase Cancer Center. (April, 2015. 11 min.)
Dr. Bilusic talks to Harry Hurley, WPG 1450 AM, April 2015
- Joseph Lindsay - Bladder Cancer Patient Stories
Prostate cancer, Bladder Cancer, Kidney Cancer, Testicular Cancer, Penile Cancer, Adrenal Cancer.
Croatian and Serbian spoken.
Diplomate, Internal Medicine, ABIM;
Medical Oncology, ABIM
We live in a very special time in history of cancer treatments, with many challenges, but also the opportunity for making paradigm shifts in the way we think of and treat cancer.
I am interested in genitourinary cancers (prostate, bladder, kidney, and testicular cancers). I am also interested in developing new treatment options for cancers, including cancer immunotherapy. The main premise is stimulating the patient's immune system using vaccine, antibodies or immune modulators to attack and kill the malignant tumor cells that are responsible for the disease.
In addition, I am passionate about translational research and clinical trials. Only a minority of adult cancer patients participate in cancer clinical trials. Clinical trial enrollment depends on well designed trials, educated patients, insurance companies, and institutional infrastructure support. The treatments we have today are built upon the clinical trial results and patient participation of the past. My goal is to offer patients the best treatment option available for their disease, including clinical trials.
My PhD research was in physiological genomic. In common speech, "gene" is often used to refer to the hereditary cause of a trait, disease, or condition. Physiological genomic is the study of how genes and the interplay between genes and environment affect “complex” diseases, including cancer. Everyone is an individual. I believe that personalized approach also applies to how I care for patients.
PhD, University of Split - School of Medicine Split, Croatia, 2005
MD, University of Zagreb – School of Medicine Zagreb, Croatia. 1996
Seton Hall University, School of Graduate Medical Education
National Cancer Institute / National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD;
Department of Physiology, Human and Molecular Genetic Centre, Medical College of Wisconsin, Milwaukee, WI
American College of Physicians;
American Society of Clinical Oncology
Tumor immunology and development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, or immune modulators.
Dr. Bilusic on My NCBI
- Norberg SM, Oros M, Manucha V, Eun D, Bilusic M. Loss of e-cadherin and retinoblastoma genes in a case of urothelial carcinoma with scrotal metastasis. Can J Urol. 2015 Apr;22 (2):7755-7.
- Ito T, Bilusic M, Chen D. Targeted radionuclides for prostate cancer bone metastases. Urol Oncol. 2015 Jan;33(1):2-6
- Norberg SM, Oros M, Birkenbach M, Bilusic M. Spontaneous tumor lysis syndrome in renal cell carcinoma: a case report. Clin Genitourin Cancer. 2014 Oct;12(5):e225-7
- Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl. 2014 May-Jun;16(3):372-7.
- Bilusic M, Heery CR, Arlen PM, Rauckhorst M, Apelian D, Tucker JA, Jochems C, Schlom J, Gulley JL, and Madan RA. Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. Cancer Immunol Immunother. 2014 Mar;63(3):225-34
- Madan RA, Tsang KY, Bilusic M, Vergati M, Poole DJ, Jochems C, Tucker JA, Schlom J, Giaccone G, Gulley JL. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer. Oncologist. 2013; 18 (7):821-2.
- Bilusic M, Madan R and Gulley JL. Issues in pre-clinical models, clinical trial design and analytical considerations in developing and evaluating novel cancer immunotherapies. Curiel T (ed). In: Cancer Immunotherapy: Paradigms, Practice and Promise. New York: Springer Science + Business Media; 455-474, 2013.
- Kim JW, Bilusic M, Heery CR and Madan RA: Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers (Basel) 2012 Nov 22; 4(4):1229-46.
- Madan RA, Bilusic M, Heery CR, Schlom J, Gulley JL. Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol. 2012 Jun; 39(3):296-304.
- Bilusic M, Gulley JL: Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother. 2012 Jan;61(1):109-17
- Bilusic M and Madan RA. Therapeutic Cancer Vaccines: The Latest Advancement in Targeted Therapy. Am J Ther. 2012 Nov; 19(6):e172-81.
- Bilusic M, Heery CR and Madan RA. Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. Vaccine. 2011 Sep 2; 29 (38):6485-97.
- Bilusic M and Dahut WL: Cabazitaxel: a new drug for metastatic prostate cancer” Asian J Androl. 2011 Mar;13(2):185-6
- Heery CR, Bilusic M and Madan RA. & Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward. Gulley J and Abraham J (eds). In: Emerging Cancer Therapeutics Volume 2, Issue 3: Prostate Cancer. New York: Demos Medical Publishing; 597-612, 2011.